Patents by Inventor Xiaoling Chen

Xiaoling Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11702392
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: July 18, 2023
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • Patent number: 11512069
    Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: November 29, 2022
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • Patent number: 11209414
    Abstract: Provided is a method for determining a quality level of an iron and steel product. The method includes: obtaining a plurality of first parameters related to a quality of an iron and steel product; fusing the plurality of first parameters to obtain a comprehensive quality evaluation parameter; and determining a quality level of the iron and steel product based on the comprehensive quality evaluation parameter.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: December 28, 2021
    Assignees: Central Iron and Steel Research Institute, BEIJING MATDAO TECHNOLOGY CO., LTD.
    Inventors: Hang Su, Tao Pan, Xiaoling Chen, Caifu Yang, Feng Chai, Qingyou Liu
  • Publication number: 20210300940
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: July 29, 2019
    Publication date: September 30, 2021
    Applicant: Merck Patent GmbH
    Inventors: Brian Sherer, Ruoxi Lan, Nadia Brugger, Xiaoling Chen, Momar Toure, Esther Cleary, Lizbeth Celeste Deselm, Yanping Wang
  • Publication number: 20210179565
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 17, 2021
    Inventors: Catherine JORAND-LEBRUN, Roch BOIVIN, Theresa JOHNSON, Yanping WANG, Yufang XIAO, Xiaoling CHEN, Nina LINDE, Doreen MUSCH, Deepak KUMAR
  • Patent number: 11001561
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • Patent number: 10947214
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • Publication number: 20210002256
    Abstract: A compound of Formula I or pharmaceutically acceptable compositions thereof, is useful to as a TLR7/8 antagonist.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • Publication number: 20210002255
    Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Inventors: Brian A. SHERER, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • Publication number: 20200369648
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 26, 2020
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • Patent number: 10836750
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: November 17, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • Publication number: 20200317622
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 8, 2020
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • Patent number: 10793553
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 6, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • Patent number: 10517872
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 31, 2019
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Ruoxi Lan, Catherine Jorand-Lebrun, Henry Yu, Andreas Goutopoulos
  • Patent number: 10287300
    Abstract: The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula I, and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: May 14, 2019
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Yufang Xiao
  • Publication number: 20190137471
    Abstract: Provided is a method for determining a quality level of an iron and steel product. The method includes: obtaining a plurality of first parameters related to a quality of an iron and steel product; fusing the plurality of first parameters to obtain a comprehensive quality evaluation parameter; and determining a quality level of the iron and steel product based on the comprehensive quality evaluation parameter.
    Type: Application
    Filed: October 19, 2018
    Publication date: May 9, 2019
    Inventors: Hang SU, Tao PAN, Xiaoling CHEN, Caifu YANG, Feng CHAI, Qingyou LIU
  • Patent number: 10233160
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: March 19, 2019
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste DeSelm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Publication number: 20190023687
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Application
    Filed: July 17, 2018
    Publication date: January 24, 2019
    Inventors: Brian A. SHERER, Nadia BRUGGER, Ruoxi LAN, Xiaoling CHEN
  • Patent number: D919605
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: May 18, 2021
    Inventor: Xiaoling Chen
  • Patent number: D945602
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: March 8, 2022
    Inventor: Xiaoling Chen